TAUNS Laboratories, Inc. (Ticker: 197A.T) is a pharmaceutical company specializing in the development, manufacturing, and sale of rapid diagnostic test kits for infectious diseases. The company's products are used by medical institutions for point-of-care testing to provide timely and accurate diagnoses. Founded in 1987, TAUNS Laboratories manufactures in vitro diagnostic test kits and research reagents, and its products are used in Japan and globally. The company will list on June 20, 2024, in Japan. TAUNS Laboratories is offering 24,253,500 shares at an IPO price of ¥460 per share. The total offer size is ¥11,156,610,000 (USD 77,484,264). The offering is managed by Daiwa, Mitsubishi UFJ Morgan Stanley Securities Co., Ltd., and other underwriters.